ResearchMoz

China Diagnostic Reagent Industry Report, 2012-2014

Research In China
Published Date » 2013-01-04
No. Of Pages » 86
   
 Chinas diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in Chinas medical care investment and per capita health care spending, the Chinas diagnostic reagent market has a promising prospect.  
   
 In vitro diagnostic reagents account for more than 90.0% of the output of Chinas diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.  
   
 At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in Chinas diagnostic...
Table of Content

1. Overview of Diagnostic Reagent Industry
1.1 Definition
1.2 Classification

2. China Diagnostic Reagent Industry

2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competitive Landscape
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win

5. Major Chinese Diagnostic Reagent Enterprises

5.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R & D and Investment
5.1.6 Customers
5.1.7 Diagnostic Reagent Business
5.1.8 Forecast and Prospect
5.2 Da An Gene Co., Ltd.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R & D and Investment
5.2.6 Diagnostic Reagent Business
5.2.7 Forecast and Prospect
5.3 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R & D and Investment
5.3.6 Diagnostic Reagent Business
5.3.7 Forecast and Prospect
5.4 BioSino Bio-technology and Science Inc.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 R & D and Investment
5.4.5 Forecast and Prospect
5.5 Beijing Kinghawk Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 Diagnostic Reagent Business
5.5.6 Forecast and Prospect
5.6 Livzon Pharmaceutical Group Inc.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Diagnostic Reagent Business
5.6.6 Forecast and Prospect
5.7 Beijing Leadman Biochemistry Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.7.3 Revenue Structure
5.7.4 Gross Margin
5.7.5 R & D and Investment
5.7.6 Customers
5.7.7 Diagnostic Reagent Business
5.7.8 Forecast and Prospect
5.8 Acon Biotech (Hangzhou) Co., Ltd.
5.8.1 Profile
5.8.2 Operation
5.8.3 Development
5.9 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.9.3 Development
5.10 Shanghai Rongsheng Biotech Co., Ltd. (Rsbio)
5.10.1 Profile
5.10.2 Operation
5.10.3 Development
5.11 Shenzhen PG Biotech Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 Shanghai Upper Bio-Tech Pharma Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.12.3 Development
5.13 Inverness Medical (Shanghai) Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Blue Cross Bio-Medical (Beijing) Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.14.3 Development
5.15 Beijing North Institute of Biological Technology (BNIBT)
5.15.1 Profile
5.15.2 Operation
5.15.3 Development

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Poland: mortars market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the mortars market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the mortars market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Rubber Tires Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2013 - 2019
By - Transparency Market Research
The world runs on wheels, and almost all automotive-wheels essentially need tires.  Modern pneumatic tire production fundamentally needs synthetic or natural rubber along with other chemicals. A huge majority of the world rubber production is consumed by the tire industry. The crucial performance requirements of automotive-tires are to provide grip to the vehicle, resist abrasion, and carry and transport loads, all the while providing reasonable safety and performance to the vehicle. Different types of rubber are used for manufacturing tires for different purposes. The tire...
Male Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Cancer, according to the WHO resulted in the death of around 8.2 million individuals worldwide in 2012. Around 14% of the world’s total annual deaths are as a result of various cancers. Modern medicine has extended the life expectancy of a cancer patient by a great margin. However newer cases are diagnosed every year globally, there is at present 14 million newly diagnosed individuals annually, according to the WHO. This is commonly as a result of the changing lifestyles, unhealthy diet, hereditary factors and exposure to carcinogenic elements. Nearly half of the general...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Pepsi Limon, A Brand New Addition to the Pepsi Portfolio
May 22, 2015  
To add a new dose of excitement to its cola offering, Pepsi has come up with the all new Pepsi Limon. This is a new flavored cola, which according to the company is manufactured with just the appropriate amount of real lime juice. The idea for the drink was inspired from the escalating preference of the Hispanic consumers. To satisfy the taste urges of the consumers, the new Pepsi Limon will...
Chinese Everbright Healthcare Fund to Acquire U.S. Firm Ambrx
May 22, 2015  
A group led by Chinese healthcare fund Everbright has chalked out details to buy U.S. based biotechnology firm Ambrx for an amount which in undisclosed. The deal, recently announces, is inclusive of other healthcare companies in mainland which are WuXi Pharma Tech and Shanghai Fosun Pharmaceutical, and investment company HOPU Investments.  The deal, which requires...
India’s Auto Exports Register Record High Figures in 2014-15
May 21, 2015  
In the fiscal year 2014-15, Indian factories exported a record number of 3.5 million vehicles, which is 15% higher than what they managed a year back. However, domestic sales rose by only 5% since last financial year, with 2.6 million units being sold.  Exports of utility vehicles, commercial vehicles, cars and two- wheelers have increased every year since 2000. But domestic car...
Turkey’s Labor Dispute Affects Ford’s Production
May 21, 2015  
With the ongoing labor dispute in Turkey, Ford’s Turkish manufacturing facility has been hit. Ford Otosan, a joint venture between the company and Turkey’s Koc Holding, mentioned that due to supply problems, production has been temporary stalled at its plants located at Yenikoy and Golcuk in northwestern part of the country. Earlier this week, production at Tofas and Oyak Renault,...
International Automakers Slashing Prices in China
May 21, 2015  
With a slowing Chinese economy, the international automakers are cutting prices of vehicles to be sold in the nation. This has hit the profit margins of the automakers who are struggling with a slowdown in demand.  Last week saw Ford Motor Co. and General Motors slashing their prices on Chinese models. It closely follows rival Volkswagen AG’s move last month to offer...